The Danish biotech industry has seen a surge in investments in the last six months, reports national daily newspaper Berlingske Tidende. In total, DKK 975 m (USD 165.6 m) was invested in the industry over that period. Niels Gerner Larsen, head of analysis of Medicon Valley Academy comments:
"Things started to improve in 2005, and right now it looks as if this year will be even better. In the past six months we have seen large capital rounds, and the new trend is that money is increasingly coming from abroad."
According to analysts, Medicon Valley, the Danish-Swedish biotech cluster, is ranked fourth in Europe in terms of drugs in late development phases. This is also part of the reason why the industry is attracting increasing investments. Henrik Lawaetz, managing director of Scandinavian Life Science Venture observes:
"If one looks at the Danish biotech landscape, it is a far more mature industry compared to five years ago. In our view this is primarily because a number of companies have well advanced clinical trial programmes. This leads to larger investments from investors."
Among the largest investments in the last six months are DKK 216 m (USD 36.7 m) to Zealand Pharma, DKK 140 m (USD 23.8 m) to 7TM Pharma and DKK 187 (USD 31.8 m) from an IPO of Curalogic.